<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="776 doi: 10.1186/s10194-017-0776-4 : Research Article Is topiramate effective for" exact="migraine" post="prevention in patients less than 18 years of age?"/>
 <result pre="used to prevent pediatric migraines. Topiramate has been approved for" exact="migraine" post="prevention in children as young as 12 years of"/>
 <result pre="currently published data pertaining to the efficacy of topiramate for" exact="migraine" post="prevention in patients less than 18 years of age."/>
 <result pre="it has been recognized as one of the most prevalent" exact="neurological disorder" post="in children and adolescents worldwide, affecting 5–10% of the"/>
 <result pre="harmony [ 1, 2]. The mean age of onset of" exact="migraine" post="is 7.2 years in boys and 10.9 years in"/>
 <result pre="10.9 years in girls [ 3], and the prevalence of" exact="migraine" post="increases with age, as demonstrated by clinical studies. The"/>
 <result pre="age, as demonstrated by clinical studies. The diagnostic criteria for" exact="migraine" post="headaches have developed over time; modern migraine classification includes"/>
 <result pre="diagnostic criteria for migraine headaches have developed over time; modern" exact="migraine" post="classification includes frequency as a criterion, with episodic headaches"/>
 <result pre="headaches occurring up to 14 days per month, and chronic" exact="migraine" post="is defined as the persistence of headache without aura"/>
 <result pre="to the harm caused by migraines, reducing the number of" exact="migraine" post="attacks to the greatest extent possible should be a"/>
 <result pre="positive efficacy and safety for older children and adults with" exact="epilepsy" post="[ 6], and it has been approved for migraine"/>
 <result pre="with epilepsy [ 6], and it has been approved for" exact="migraine" post="prevention in adults in Europe since 2003 and in"/>
 <result pre="7]. The exact mechanism of topiramate in the treatment of" exact="migraine" post="is unknown, although it may be associated with the"/>
 <result pre="to evaluate the efficacy of topiramate for the prevention of" exact="migraine" post="in patients less than 18 years of age. Methods"/>
 <result pre="to April 2017) to retrieve the RCTs of topiramate in" exact="migraine" post="prevention for patients less than 18 years of age."/>
 <result pre="the study was a trial comparing topiramate with placebo in" exact="migraine" post="patients, (2) the study had similar diagnostic criteria for"/>
 <result pre="migraine patients, (2) the study had similar diagnostic criteria for" exact="migraine" post="or definition of migraine, (3) the age of the"/>
 <result pre="employed the International Headache Society (IHS) diagnostic criteria for pediatric" exact="migraine" post="and 3 trials [ 14, 18, 19] used the"/>
 <result pre="Paul Winner,2005 International Headache Society (IHS) diagnostic criteria for pediatric" exact="migraine" post="108 11.3 ± 2.5 50.9:49.1 8-week: Week 1 ="/>
 <result pre="2 weeks 16-week: average 1.93 ± 0.40 mg mg/Kg.d aphasia," exact="cognitive disorder," post="dizziness, memory impairment, paresthesia, general: fatigue, dry mouth, intussusception,"/>
 <result pre="all 4 included trials investigated the effects of topiramate on" exact="migraine" post="prevention via the numbers of patients experiencing a ≥"/>
 <result pre="fatigue, injury, upper respiratory tract infection, dizziness, fever, nausea, pharyngitis," exact="sinusitis" post="and somnolence) of topiramate versus placebo(*There was a significant"/>
 <result pre="trials indicate that a clinically meaningful end point in a" exact="migraine" post="prevention trial is usually defined by a reduction in"/>
 <result pre="the U.S. Food and Drug Administration (FDA) approved topiramate for" exact="migraine" post="prevention in the population aged 12 to 17 ["/>
 <result pre="the first and only medication currently approved for use in" exact="migraine" post="patients 12 years and over. Nevertheless, neither the primary"/>
 <result pre="age-dependent placebo response has ranged from 30% to 70% in" exact="migraine" post="studies in general [ 24– 27]. The outcome of"/>
 <result pre="the rates reported in previous studies of topiramate preventing adult" exact="migraine" post="(0–34.2%) [ 28– 31]. Rothner et al. [ 32]"/>
 <result pre="neurotransmitter systems may explain the differences. 2. The characteristics of" exact="migraine" post="attacks are different [ 34]: migraine headaches in children"/>
 <result pre="2. The characteristics of migraine attacks are different [ 34]:" exact="migraine" post="headaches in children and adolescents are often bilateral and"/>
 <result pre="minimum age at which topiramate was approved for treatment of" exact="migraine" post="was 12 years old, but the minimum age of"/>
 <result pre="Our included patients included those with either episodic or chronic" exact="migraine" post="[ 14], which may influence the results of our"/>
 <result pre="of our meta-analysis is that topiramate decreased PedMIDAS scores in" exact="migraine" post="patients. PedMIDAS is often used to measure disability related"/>
 <result pre="placebo in our included trials. It has been reported that" exact="metabolic acidosis," post="renal calculi and nervous system effects, such as fatigue"/>
 <result pre="system effects, such as fatigue or somnolence, paresthesia, dizziness and" exact="cognitive disorder" post="or aphasia, occurred in adults and pediatric patients taking"/>
 <result pre="drugs, including topiramate [ 39]. Thus, while the pathomechanism of" exact="migraine" post="is not completely understood, the choice of medication for"/>
 <result pre="limitations. Conclusions This is the first meta-analysis of topiramate for" exact="migraine" post="prevention in patients less than 18 years of age."/>
 <result pre="effective clinical trial endpoint than placebo in the prevention of" exact="migraine" post="in patients less than 18 years of age, and"/>
 <result pre="response rate can be beneficial for children and adolescents with" exact="migraine" post="and that drugs used to prevent pediatric migraine might"/>
 <result pre="adolescents with migraine and that drugs used to prevent pediatric" exact="migraine" post="might be reconsidered. Because there was a significant placebo"/>
 <result pre="a significant placebo response, more placebo-controlled trials in the younger" exact="migraine" post="population less than 12 years of age are needed."/>
 <result pre="affiliations. References References 1. Split W Neuman W Epidemiology of" exact="migraine" post="among students from randomly selected secondary schools in Lodz"/>
 <result pre="7 494 501 10.1046/j.1526-4610.1999.3907494.x 11279934 2. Kacperski J Prophylaxis of" exact="migraine" post="in children and adolescents Paediatr Drugs 2015 17 3"/>
 <result pre="D Yonker M Silberstein S Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
 <result pre="Bolzonella B Sartori S Battistella PA The pharmacological treatment of" exact="migraine" post="in children and adolescents: an overview Expert Rev Neurother"/>
 <result pre="Schmitt J Neto W Schwabe S Jacobs D Topiramate for" exact="migraine" post="prevention: a randomized controlled trial JAMA 2004 291 8"/>
 <result pre="S Goadsby PJ Efficacy and mechanism of anticonvulsant drugs in" exact="migraine" post="Expert Rev Clin Pharmacol 2014 7 2 191 201"/>
 <result pre="Casas C Herranz JL Topiramate in the prophylactic treatment of" exact="migraine" post="in children J Child Neurol 2005 20 3 251"/>
 <result pre="15832623 10. Anand KS Dhikav V Aggarwal J Topiramate for" exact="migraine" post="prophylaxis Indian Pediatr 2012 49 4 329 330 10.1007/s13312-012-0040-6"/>
 <result pre="22565082 11. Abbaskhanian ASHREAMS Effective dose of topiramate in pediatric" exact="migraine" post="prophylaxis In J Pediatr Neurosci 2012 7 171 174"/>
 <result pre="Mirouliaei M Shamszadeh A Topiramate and propranolol for prophylaxis of" exact="migraine" post="Indian J Pediatr 2013 80 11 920 924 10.1007/s12098-013-0976-0"/>
 <result pre="Hershey AD Trial of Amitriptyline, Topiramate, and placebo for pediatric" exact="migraine" post="N Engl J Med 2017 376 2 115 124"/>
 <result pre="study to evaluate the efficacy and safety of topiramate for" exact="migraine" post="prevention in pediatric subjects 12 to 17 years of"/>
 <result pre="Linder SL Jordan DM Fisher AC Hulihan J Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
 <result pre="1 6 38 10.1177/0333102411430849 23. 2014) FDA approves Topamax for" exact="migraine" post="prevention in adolescents. J Pain Palliat Care Pharmacother, 28(2):191"/>
 <result pre="AD Current approaches to the diagnosis and management of paediatric" exact="migraine" post="Lancet Neurol 2010 9 2 190 204 10.1016/S1474-4422(09)70303-5 20129168"/>
 <result pre="K Hamalainen M Hoppu K Children’s response to placebo in" exact="migraine" post="attacks Cephalalgia Int J Headache 2000 20 385 10.1046/j.1468-2982.2000.00089.x"/>
 <result pre="RB Placebo response in clinical randomized trials of analgesics in" exact="migraine" post="Cephalalgia An Int J Headache 2003 23 7 487"/>
 <result pre="Lebel A Borsook D Harnessing the placebo effect in pediatric" exact="migraine" post="clinic J Pediatr 2014 165 4 659 665 10.1016/j.jpeds.2014.06.040"/>
 <result pre="and tolerability of topiramate 200 mg/d in the prevention of" exact="migraine" post="with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week"/>
 <result pre="trials on the efficacy of topiramate in the prevention of" exact="migraine" post="J Am Osteopath Assoc 2007 107 7 251 258"/>
 <result pre="V Shukla G Behari M Low-dose topiramate versus lamotrigine in" exact="migraine" post="prophylaxis (the Lotolamp study) Headache 2007 47 3 402"/>
 <result pre="Winner P Lewis D Stankowski J Zolmitriptan oral tablet in" exact="migraine" post="treatment: high placebo responses in adolescents Headache 2006 46"/>
 <result pre="HC Sances G Bono G Lessons from placebo effects in" exact="migraine" post="treatment J Headache Pain 2007 8 1 63 66"/>
 <result pre="200 10.1016/S1364-6613(03)00061-5 12757820 37. Oakley CB Kossoff EH Migraine and" exact="epilepsy" post="in the pediatric population Curr Pain Headache Rep 2014"/>
 <result pre="M Bilder RM Ford L Cognitive effects of topiramate in" exact="migraine" post="patients aged 12 through 17 years Pediatr Neurol 2010"/>
 <result pre="Szok D Csáti A Vécsei L Prophylactic drug treatment of" exact="migraine" post="in children and adolescents: an update Curr Pain Headache"/>
</results>
